n-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity

C. S. Berenson, M. A. Patterson, J. A. Miqdadi, Michael P Lance

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

1. n-Butyrate, a short chain fatty acid produced by colonic fermentation, induces differentiation in human neoplastic cell lines, and reduces expression in vitro of a sialyltransferase that glycosylates N-linked glycoproteins in hepatoblastoma cells. Gangliosides are amphipathic, sialylated glycosphingolipids that undergo profound changes in many transformed cells and may protect neoplastic cells from host immune surveillance. Colonic mucosal cells are exposed to luminal short-chain fatty acid concentrations of up to 80 mmol/l, and there is some evidence that short-chain fatty acids may alter ganglioside expression in colon cancer cells. 2. Because of the importance of gangliosides in cancer pathogenesis, we investigated the effects of n-butyrate on ganglioside expression of colonic (human and murine) and non-colonic cancer cells. 3. Three separate colon cancer cell lines (LS174T, T84 and MCA-38), when butyrate treated, demonstrated striking amplification of specific individual gangliosides. However, the total lipid-hound sialic acid content of gangliosides of butyrate-treated LS174T cells diminished. In contrast to earlier reports, n-butyrate did not mediate expression of all gangliosides and specifically did not mediate expression of G(M3). This effect persisted even after removal of butyrate. 4. In contrast, exposure of extracolonic cells to butyrate, including cervical cancer (HeLa) and laryngeal cancer (HEp-2) cell lines in this study and hepatoblastoma cells (Hep G2) in our previous work, caused no detectable changes in ganglioside expression. 5. In conclusion, our results indicate a relative tissue specificity of butyrate-mediated alterations in ganglioside expression that is not universal but is limited to specific gangliosides.

Original languageEnglish (US)
Pages (from-to)491-499
Number of pages9
JournalClinical Science
Volume88
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Butyrates
Gangliosides
Neoplasms
Volatile Fatty Acids
Hepatoblastoma
Cell Line
Colonic Neoplasms
Sialyltransferases
Glycosphingolipids
Organ Specificity
Laryngeal Neoplasms
Hep G2 Cells
N-Acetylneuraminic Acid
Uterine Cervical Neoplasms
Fermentation
Glycoproteins
Lipids

Keywords

  • Colon cancer
  • Gangliosides
  • n-Butyrate
  • Sialic acid

ASJC Scopus subject areas

  • Medicine(all)

Cite this

n-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity. / Berenson, C. S.; Patterson, M. A.; Miqdadi, J. A.; Lance, Michael P.

In: Clinical Science, Vol. 88, No. 4, 1995, p. 491-499.

Research output: Contribution to journalArticle

@article{038638b57a8a4b528464fd49eccb10ab,
title = "n-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity",
abstract = "1. n-Butyrate, a short chain fatty acid produced by colonic fermentation, induces differentiation in human neoplastic cell lines, and reduces expression in vitro of a sialyltransferase that glycosylates N-linked glycoproteins in hepatoblastoma cells. Gangliosides are amphipathic, sialylated glycosphingolipids that undergo profound changes in many transformed cells and may protect neoplastic cells from host immune surveillance. Colonic mucosal cells are exposed to luminal short-chain fatty acid concentrations of up to 80 mmol/l, and there is some evidence that short-chain fatty acids may alter ganglioside expression in colon cancer cells. 2. Because of the importance of gangliosides in cancer pathogenesis, we investigated the effects of n-butyrate on ganglioside expression of colonic (human and murine) and non-colonic cancer cells. 3. Three separate colon cancer cell lines (LS174T, T84 and MCA-38), when butyrate treated, demonstrated striking amplification of specific individual gangliosides. However, the total lipid-hound sialic acid content of gangliosides of butyrate-treated LS174T cells diminished. In contrast to earlier reports, n-butyrate did not mediate expression of all gangliosides and specifically did not mediate expression of G(M3). This effect persisted even after removal of butyrate. 4. In contrast, exposure of extracolonic cells to butyrate, including cervical cancer (HeLa) and laryngeal cancer (HEp-2) cell lines in this study and hepatoblastoma cells (Hep G2) in our previous work, caused no detectable changes in ganglioside expression. 5. In conclusion, our results indicate a relative tissue specificity of butyrate-mediated alterations in ganglioside expression that is not universal but is limited to specific gangliosides.",
keywords = "Colon cancer, Gangliosides, n-Butyrate, Sialic acid",
author = "Berenson, {C. S.} and Patterson, {M. A.} and Miqdadi, {J. A.} and Lance, {Michael P}",
year = "1995",
language = "English (US)",
volume = "88",
pages = "491--499",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "4",

}

TY - JOUR

T1 - n-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity

AU - Berenson, C. S.

AU - Patterson, M. A.

AU - Miqdadi, J. A.

AU - Lance, Michael P

PY - 1995

Y1 - 1995

N2 - 1. n-Butyrate, a short chain fatty acid produced by colonic fermentation, induces differentiation in human neoplastic cell lines, and reduces expression in vitro of a sialyltransferase that glycosylates N-linked glycoproteins in hepatoblastoma cells. Gangliosides are amphipathic, sialylated glycosphingolipids that undergo profound changes in many transformed cells and may protect neoplastic cells from host immune surveillance. Colonic mucosal cells are exposed to luminal short-chain fatty acid concentrations of up to 80 mmol/l, and there is some evidence that short-chain fatty acids may alter ganglioside expression in colon cancer cells. 2. Because of the importance of gangliosides in cancer pathogenesis, we investigated the effects of n-butyrate on ganglioside expression of colonic (human and murine) and non-colonic cancer cells. 3. Three separate colon cancer cell lines (LS174T, T84 and MCA-38), when butyrate treated, demonstrated striking amplification of specific individual gangliosides. However, the total lipid-hound sialic acid content of gangliosides of butyrate-treated LS174T cells diminished. In contrast to earlier reports, n-butyrate did not mediate expression of all gangliosides and specifically did not mediate expression of G(M3). This effect persisted even after removal of butyrate. 4. In contrast, exposure of extracolonic cells to butyrate, including cervical cancer (HeLa) and laryngeal cancer (HEp-2) cell lines in this study and hepatoblastoma cells (Hep G2) in our previous work, caused no detectable changes in ganglioside expression. 5. In conclusion, our results indicate a relative tissue specificity of butyrate-mediated alterations in ganglioside expression that is not universal but is limited to specific gangliosides.

AB - 1. n-Butyrate, a short chain fatty acid produced by colonic fermentation, induces differentiation in human neoplastic cell lines, and reduces expression in vitro of a sialyltransferase that glycosylates N-linked glycoproteins in hepatoblastoma cells. Gangliosides are amphipathic, sialylated glycosphingolipids that undergo profound changes in many transformed cells and may protect neoplastic cells from host immune surveillance. Colonic mucosal cells are exposed to luminal short-chain fatty acid concentrations of up to 80 mmol/l, and there is some evidence that short-chain fatty acids may alter ganglioside expression in colon cancer cells. 2. Because of the importance of gangliosides in cancer pathogenesis, we investigated the effects of n-butyrate on ganglioside expression of colonic (human and murine) and non-colonic cancer cells. 3. Three separate colon cancer cell lines (LS174T, T84 and MCA-38), when butyrate treated, demonstrated striking amplification of specific individual gangliosides. However, the total lipid-hound sialic acid content of gangliosides of butyrate-treated LS174T cells diminished. In contrast to earlier reports, n-butyrate did not mediate expression of all gangliosides and specifically did not mediate expression of G(M3). This effect persisted even after removal of butyrate. 4. In contrast, exposure of extracolonic cells to butyrate, including cervical cancer (HeLa) and laryngeal cancer (HEp-2) cell lines in this study and hepatoblastoma cells (Hep G2) in our previous work, caused no detectable changes in ganglioside expression. 5. In conclusion, our results indicate a relative tissue specificity of butyrate-mediated alterations in ganglioside expression that is not universal but is limited to specific gangliosides.

KW - Colon cancer

KW - Gangliosides

KW - n-Butyrate

KW - Sialic acid

UR - http://www.scopus.com/inward/record.url?scp=0028899976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028899976&partnerID=8YFLogxK

M3 - Article

C2 - 7789051

AN - SCOPUS:0028899976

VL - 88

SP - 491

EP - 499

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 4

ER -